FTOX030 ABCB1 haplotypes enhances the effect of CYP3A5 polymorphism on tacrolimus pharmacokinetics after kidney transplantation.

Autores

  • Diego Cusinato
  • Riccardo Lachinni
  • Elen Romão
  • Eduardo Coelho

Resumo

Tacrolimus (TAC) is widely used to prevent acute rejection following solid-organ transplantation and it’s known to be substrate of cytochrome P450 (CYP) 3A5 and P-glycoprotein (ABCB1). Studies have shown that genetic polymorphisms (SNPs) of CYP3A5 proteins are highly associated with variations in TAC pharmacokinetics with controversial results regarding the ABCB1 polymorphisms. Some works have showed a strong linkage disequilibrium among the highly frequent ABCB1 polymorphisms 1236C>T (rs1128503), 2677G>A/T (rs2032582) and 3435C>T (rs1045642) but no study has assessed the linkage between CYP3A5 and the ABCB1 polymorphisms so far.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2012-12-27

Como Citar

CUSINATO, D.; LACHINNI, R.; ROMÃO, E.; COELHO, E. FTOX030 ABCB1 haplotypes enhances the effect of CYP3A5 polymorphism on tacrolimus pharmacokinetics after kidney transplantation. Revista Eletrônica de Farmácia, Goiânia, v. 9, n. 1, p. 1, 2012. Disponível em: https://revistas.ufg.br/REF/article/view/21884. Acesso em: 23 maio. 2022.

Edição

Seção

Artigos Originais